false 0001477845 0001477845 2024-12-04 2024-12-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 4, 2024

 

  

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 

Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

 

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 4, 2024, Annovis Bio, Inc. (“Annovis”) appointed William Fricker, age 61, to serve as Chief Financial Officer on an interim basis. Mr. Fricker most recently served as Chief Financial Officer of NeuroTrauma Sciences from December 2023 to April 2024. Prior to NeuroTrauma Sciences, Mr. Fricker served as an independent contractor providing CFO services to biotech companies from September 2021 to November 2023. From November 2020 to August 2021, Mr. Fricker served as CFO for NRX Pharmaceuticals, taking the Company public in May of 2020. Mr. Fricker served as Chief Accounting Officer for Immunomedics from February 2018 to the sale of the Company to Gilead in October 2020. Mr. Fricker started his career at PriceWaterhouseCoopers and has held management positions as Bristol Myers Squibb, Johnson & Johnson and Tyco. Mr. Fricker graduated from Penn State University with a B.S. in Accounting and is a CPA (Inactive). There are no transactions between Mr. Fricker and Annovis of the type required to be disclosed by Item 404(a) of Regulation S-K.

 

Mr. Fricker is serving on a contract basis and is not a party to any employment agreement or similar arrangement with Annovis.

 

Item 9.01  Financial Statements and Exhibits. 

 

(d) Exhibits.

 

Exhibit No.    Description
104   Cover Page Interactive Data File

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: December 9, 2024 By: /s/ Maria Maccecchini
    Name: Maria Maccecchini
    Title: President and Chief Executive Officer

 

 

 

v3.24.3
Cover
Dec. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 04, 2024
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 101 Lindenwood Drive
Entity Address, Address Line Two Suite 225
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 875-3192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Annovis Bio Charts.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Annovis Bio Charts.